Research led by a Monash University scientist has identified a highly conserved mechanism in worms and humans that controls the removal of toxic protein aggregates -- hallmarks of neurodegenerative diseases.

The ECOG-ACRIN Cancer Research Group today announced results from extended follow-up of patients in its randomized Phase 3 clinical trial, E1912. Previously untreated patients (aged 70 or younger) with chronic lymphocytic leukemia (CLL) who received ibrutinib-based therapy lived longer and with sustained benefit, compared to standard FCR chemoimmunotherapy. The updated analysis supports the...

For older patients with AML, the prospects for success of a stem cell transplant can often be predicted based on the particular set of genetic mutations within the tumor cells, investigators at Dana-Farber Cancer Institute will report at the ASH Annual Meeting.

A new, experimental immunotherapy can put patients with B-cell non-Hodgkin lymphoma (NHL) that is resistant to or has come back after multiple other therapies, including CAR T therapy, into remission.

For patients with high-risk myeloid cancers undergoing a donor stem cell transplant, adding the targeted drug venetoclax to a reduced-intensity drug regimen prior to transplant is safe and does not impair the ability of the donor cells to take root in recipients' bodies.